exenatide + insulin aspart

Exenatide + insulin aspart is a combination therapy used in the management of type 2 diabetes mellitus. Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, and slows gastric emptying, leading to improved glycemic control and weight loss. Insulin aspart is a recombinant fast-acting human insulin analogue that facilitates cellular glucose uptake and reduces blood glucose levels. The combination aims to leverage the complementary mechanisms of both agents for better glycemic control than either alone, with exenatide providing postprandial glucose reduction and weight benefits, while insulin aspart offers rapid correction of hyperglycemia[1][3][9]. This regimen has been studied in clinical trials for patients inadequately controlled on oral antidiabetic agents[1][4][5].